Amphastar strategy targets branded and biosimilar growth through 2027
Management outlined a strategy centered on branded and complex generics, with BAQSIMI and new biosimilars aimed to drive near-term growth. Operational improvements and pipeline expansion target margin gains and revenue diversification through 2027.
Management outlined a strategy centered on branded products and complex generics, with BAQSIMI and new biosimilars expected to support near-term growth. The company said operational improvements, pipeline expansion and targeted investments are intended to lift margins and diversify revenue through 2027.